Related Experiment Video
Updated: May 27, 2026

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
Ovulation inducing agents and cancer risk: review of literature
Gianna Gabriella Impicciatore1, Gian Mario Tiboni
1Sezione di Scienze della Riproduzione, Dipartimento di Medicina e Scienze dell’Invecchiamento, Facoltà di Medicina e Chirurgia, Università G. d'Annunzio Chieti-Pescara, Italy.
Abstract:
Over the past decades, the use of ovulation inducing drugs has been increasing. A possible causal link between fertility treatments (especially clomiphene citrate and gonadotrophins) and various types of malignancies, including cancers of female reproductive system, thyroid cancer and melanoma, has been postulated. The majority of the available studies on this subject suffers from methodological limitations, including the small number of outcomes, short and incomplete follow-up, and inability to control for potential confounders. Concerning ovarian cancer, while early studies led to the suggestion of an association between ovulation inducing agents and increased risk of malignancies, the majority of data do not support a causal link. An increased risk was recently observed in women giving birth after in vitro fertilization (IVF), but it appeared to be consequential to the infertile status rather than the effect of fertility drugs. More controversial are the results concerning breast cancer with some investigations suggesting an increased risk after exposure to ovulation inducing agents, especially clomiphene citrate, whereas others not supporting this concept. A possible trend towards an increased risk has been reported by some authors for endometrial cancer. Altogether, current data should be thus regarded as a signal for the need of further studies rather than being definitive in them.
Insights
Fertility drugs like clomiphene citrate may not increase cancer risk, despite early concerns. More research is needed to confirm findings on ovulation induction and malignancy associations.
Area of Science:
- Reproductive Medicine
- Oncology
- Epidemiology
Background:
- The use of ovulation-inducing drugs has risen, prompting investigation into potential links with various cancers.
- Concerns exist regarding fertility treatments, including clomiphene citrate and gonadotropins, and their association with malignancies.
- Existing studies often have methodological limitations, such as small sample sizes and incomplete follow-up.
Purpose of the Study:
- To evaluate the potential causal link between fertility treatments and cancer risk.
- To synthesize current evidence regarding ovulation-inducing agents and specific malignancies.
- To address the methodological shortcomings of previous research in this field.
Main Methods:
- Review and analysis of existing epidemiological studies on fertility drugs and cancer.
- Assessment of data quality, including sample size, follow-up duration, and control for confounders.
- Comparative analysis of findings across different cancer types and fertility treatments.
Main Results:
- The majority of evidence does not support a causal link between ovulation-inducing agents and ovarian cancer.
- Increased cancer risk observed after in vitro fertilization (IVF) appears related to infertility itself, not the treatment drugs.
- Evidence regarding breast cancer risk associated with clomiphene citrate is controversial and inconclusive.
- Some studies suggest a potential trend towards increased endometrial cancer risk, warranting further investigation.
Conclusions:
- Current data on fertility drugs and cancer risk are not definitive and signal the need for more robust research.
- Methodological limitations in existing studies hinder conclusive statements about malignancy risks.
- Further well-designed studies are essential to clarify the relationship between ovulation induction and cancer development.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Mutagenicity and Carcinogenicity
Mechanisms of Retrovirus-induced Cancers
